


**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Statement of financial position**  
**as of 30 June 2024**


	<b>30.06.2024</b>	<b>31.12.2023</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>Non-current assets</b>		
Property, plant and equipment	34,324	33,083
Intangible Assets and Goodwill	3,529	3,560
Trade receivables	4,978	4,978
<b>Non-current assets</b>	<b>42,831</b>	<b>41,621</b>
Inventories	14,230	14,303
Trade and other receivables	67,138	66,490
Current tax assets	-	12
Cash and cash equivalents	115	73
<b>Current Assets</b>	<b>81,483</b>	<b>80,878</b>
<b>Assets</b>	<b>124,314</b>	<b>122,499</b>
Issued capital	84,500	84,500
Statutory reserve	12,800	12,800
Retained earnings	10,508	7,701
<b>Equity</b>	<b>107,808</b>	<b>105,001</b>
<i>Equity Attributable to owners of the parent company</i>	<i>107,808</i>	<i>105,001</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	671	879
Deferred tax liabilities	1,113	1,113
Non-current provisions for employee benefits	173	197
<b>Non-current liabilities</b>	<b>1,957</b>	<b>2,632</b>
Trade and other payables	4,030	4,768
Short term borrowings	10,078	10,298
Current tax liabilities	441	243
<b>Current liabilities</b>	<b>14,549</b>	<b>15,309</b>
<b>Liabilities</b>	<b>16,506</b>	<b>17,498</b>
<b>Equity and liabilities</b>	<b>124,314</b>	<b>122,499</b>

Date of preparation: 01.08.2024

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of comprehensive income**  
**as 30 June 2024**


	<b>30.06.2024</b>	<b>30.06.2023</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	26,663	25,781
Other income	224	61
<b>Total income</b>	<b>26,887</b>	<b>25,842</b>
Carrying amount of goods sold	(1,218)	(763)
Changes in inventories of finished products and work in progress	472	354
Materials and services	(16,674)	(15,367)
Personnel expenses	(4,475)	(3,117)
Depreciation / amortisation expenses	(1,258)	(1,576)
Other expenses	(316)	(613)
Finance income	18	40
Finance costs	(374)	(308)
<b>Total expenses</b>	<b>(23,825)</b>	<b>(21,350)</b>
<b>Profit Loss before tax</b>	<b>3,062</b>	<b>4,492</b>
Current tax expense income	(255)	(210)
<b>Profit Loss</b>	<b>2,807</b>	<b>4,282</b>
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,807</i>	<i>4,282</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
<b>Other comprehensive income</b>	<b>2,807</b>	<b>4,282</b>
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
<b>Comprehensive income</b>	<b>2,807</b>	<b>4,282</b>
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,807</i>	<i>4,282</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.03	0.05

Date of preparation: 01.08.2024

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Cash flow statement**  
**as of 30 June 2024**

	<b>30.06.2024</b>	<b>30.06.2023</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>Cash flows from operating activities</b>		
Receipts from sales of goods and rendering of services	19,286	16,816
Payments to suppliers for goods and services	(9,649)	(8,791)
Payments to and on behalf of employees	(4,288)	(3,207)
Income taxes paid classified as operating activities	(243)	(183)
Other cash payments from operating activities	(3,381)	(3,089)
<b>Cash flows from used in operating activities</b>	<b>1,725</b>	<b>1,546</b>
 <b>Cash flows from investing activities</b>		
Purchase of other longterm assets classified as investing activities	(1,133)	(1,079)
<b>Cash flows from used in investing activities</b>	<b>(1,133)</b>	<b>(1,079)</b>
 <b>Cash flows from financial activities</b>		
Dividends paid classified as financing activities	298	222
Proceeds from borrowings classified as financing activities	(299)	(223)
Repayments of borrowings classified as financing activities	(288)	(222)
Payments of lease liabilities classified as financing activities	(261)	(261)
<b>Cash flows from used in financial activities</b>	<b>(550)</b>	<b>(484)</b>
 <b>Increase/Decrease in cash and cash equivalents</b>	<b>42</b>	<b>(17)</b>
<b>Cash and cash equivalents</b>	<b>73</b>	<b>142</b>
<b>Cash and cash equivalents</b>	<b>115</b>	<b>125</b>

Date of preparation: 01.08.2024

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement on changes in equity**  
**as of 30 June 2024**


	Issued capital <i>BGN'000</i>	Property plant and equipme nt revaluati on surplus <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings <i>BGN'000</i>	Equity abstract <i>BGN'000</i>	Equity Attributab le to owners of the parent company <i>BGN'000</i>	Non- controllin g interest in equity <i>BGN'000</i>
<b>Balance as of 01.01.2023</b>	<b>84,500</b>	<b>4,351</b>	<b>8,147</b>	<b>4,587</b>	<b>101,585</b>	<b>101,585</b>	-
Profit Loss	-	-	-	3,398	<b>3,398</b>	<b>3,398</b>	-
Other comprehensive income	-	18	-	-	-	-	-
<b>Comprehensive income</b>	-	<b>18</b>	-	<b>3,398</b>	<b>3,416</b>	<b>3,416</b>	-
Increase/Decrease through appropriation of retained earnings	-	-	284	(284)	-	-	-
<b>Total income expense</b>	-	-	<b>284</b>	<b>(284)</b>	-	-	-
<b>Balance as of 31.12.2023</b>	<b>84,500</b>	<b>4,369</b>	<b>8,431</b>	<b>7,701</b>	<b>105,001</b>	<b>105,001</b>	-
<b>Balance as of 01.01.2024</b>	<b>84,500</b>	<b>4,369</b>	<b>8,431</b>	<b>7,701</b>	<b>105,001</b>	<b>105,001</b>	-
Profit Loss	-	-	-	2,807	<b>2,807</b>	<b>2,807</b>	-
Other comprehensive income	-	-	-	-	-	-	-
<b>Comprehensive income</b>	-	-	-	<b>2,807</b>	<b>2,807</b>	<b>2,807</b>	-
Increase/Decrease through appropriation of retained earnings	-	-	-	-	-	-	-
<b>Total income expense</b>	-	-	-	-	-	-	-
<b>Balance as of 30.06.2024</b>	<b>84,500</b>	<b>4,369</b>	<b>8,431</b>	<b>10,508</b>	<b>107,808</b>	<b>107,808</b>	-

Date of preparation: 01.08.2024

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva